<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03846466</url>
  </required_header>
  <id_info>
    <org_study_id>4323-001</org_study_id>
    <nct_id>NCT03846466</nct_id>
  </id_info>
  <brief_title>Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis</brief_title>
  <official_title>A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Dose or Multiple Dose Study of KHK4323 in Healthy Volunteers, and Subjects With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1: To investigate the safety and tolerability of intravenous (IV) or subcutaneous (SC)&#xD;
      administration of a single dose of KHK4323 to Japanese or Caucasian healthy adult males in a&#xD;
      double-blind, placebo-controlled study.&#xD;
&#xD;
      Part 2: To investigate the safety and tolerability of intravenous (IV) administration of&#xD;
      repeated doses of KHK4323 to atopic dermatitis patients in a double-blind, placebo-controlled&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study terminated for safety reasons.&#xD;
  </why_stopped>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Actual">December 11, 2019</completion_date>
  <primary_completion_date type="Actual">December 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Part 1: from Day 1 through at most Day 169, Part 2: from Day 1 through at most Day 225</time_frame>
    <description>For adverse events that occurred after administration of the investigational drug, number of subjects with AEs and occurrence frequency are classified by MedDRA PT and SOC and shown according to dose group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics of serum KHK4323 concentration in Part 1</measure>
    <time_frame>Day 1 (pre-dose, 1, 6 hours after the start of administration) Day 2, Day 3, Day 4, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141, Day 169</time_frame>
    <description>Anti-KHK4323 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics of serum KHK4323 concentration in Part 2</measure>
    <time_frame>Day 1( pre-dose, 1 hours after the start of administration), Day 8, Day 15, Day 29,Day 43, Day 57, Day 85, Day 113, Day 169, Day 225</time_frame>
    <description>Anti-KHK4323 antibodies</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Part2: Day1(Pre-dose), Day 15, Day 29,Day 43, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 225</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Part2: Day1(Pre-dose), Day 15, Day 29,Day 43, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 225</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Body surface area (BSA) of involvement of Atopic dermatitis</measure>
    <time_frame>Part2 Day1(Pre-dose), Day 15, Day 29, Day 43, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 225</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent change in Body surface area (BSA) of involvement of Atopic dermatitis</measure>
    <time_frame>Part2 Day1(Pre-dose), Day 15, Day 29, Day 43, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 225</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number of subjects with IGA of 0 or 1 and improvement of 2 points or more over baseline score (IGA responders)</measure>
    <time_frame>Part2 Day1(Pre-dose), Day 15, Day 29, Day 43, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 225</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The percentage of subjects with IGA of 0 or 1 and improvement of 2 points or more over baseline score (IGA responders)</measure>
    <time_frame>Part2 Day1(Pre-dose), Day 15, Day 29, Day 43, Day 57, Day 85, Day 113, Day 141, Day 169, Day 197, Day 225</time_frame>
  </other_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Part1 Dose 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 Dose 1P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 Dose 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 Dose 2P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 Dose 3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 Dose 3P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 Dose 4A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 Dose 4P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 Dose 5A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 Dose 5P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 Dose 6A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 Dose 6P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 Dose 7A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 Dose 7P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2 Dose 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2 Dose 1P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2 Dose 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2 Dose 2P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK4323 IV/S</intervention_name>
    <description>IV / Single administration</description>
    <arm_group_label>Part1 Dose 1A</arm_group_label>
    <arm_group_label>Part1 Dose 2A</arm_group_label>
    <arm_group_label>Part1 Dose 3A</arm_group_label>
    <arm_group_label>Part1 Dose 4A</arm_group_label>
    <arm_group_label>Part1 Dose 6A</arm_group_label>
    <arm_group_label>Part1 Dose 7A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK4323 SC/S</intervention_name>
    <description>SC / Single administration</description>
    <arm_group_label>Part1 Dose 5A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK4323 IV/M</intervention_name>
    <description>IV / Multiple administration</description>
    <arm_group_label>Part2 Dose 1A</arm_group_label>
    <arm_group_label>Part2 Dose 2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV/S</intervention_name>
    <description>IV / Single administration</description>
    <arm_group_label>Part1 Dose 1P</arm_group_label>
    <arm_group_label>Part1 Dose 2P</arm_group_label>
    <arm_group_label>Part1 Dose 3P</arm_group_label>
    <arm_group_label>Part1 Dose 4P</arm_group_label>
    <arm_group_label>Part1 Dose 6P</arm_group_label>
    <arm_group_label>Part1 Dose 7P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV/M</intervention_name>
    <description>IV / Multiple administration</description>
    <arm_group_label>Part2 Dose 1P</arm_group_label>
    <arm_group_label>Part2 Dose 2P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SC/S</intervention_name>
    <description>SC / Single administration</description>
    <arm_group_label>Part1 Dose 5P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part 1:&#xD;
&#xD;
          -  Japanese or Caucasian male aged 20 to under 45 years old at the time consent was&#xD;
             obtained&#xD;
&#xD;
          -  BMI ≥ 18.5 to &lt; 30.0 at time of screening tests&#xD;
&#xD;
        Part 2:&#xD;
&#xD;
          -  Men and women aged 18 years or older at the time of consent&#xD;
&#xD;
          -  Patients with EASI ≥ 16 in pre-administration testing&#xD;
&#xD;
          -  Patients with IGA of &quot;3: Moderate&quot; or higher in pre-administration testing&#xD;
&#xD;
          -  Patients with BSA ≥ 10% at screening in pre-administration testing&#xD;
&#xD;
        &quot;Exclusion Criteria:&#xD;
&#xD;
        Part 1:&#xD;
&#xD;
          -  Persons with existing respiratory disease, heart disease, gastrointestinal disease,&#xD;
             kidney disease, or liver disease&#xD;
&#xD;
          -  Persons confirmed to have a bacterial, viral, fungal, or parasitic infection within 28&#xD;
             days prior to obtainment of consent&#xD;
&#xD;
          -  Persons who have contracted an infectious disease requiring hospitalization or IV&#xD;
             administration of an antibiotic within 6 months prior to obtainment of consent&#xD;
&#xD;
          -  Persons who have been treated with a biological preparation (antibody, etc.) or have&#xD;
             been administered an investigational drug within 6 months prior to the obtainment of&#xD;
             consent&#xD;
&#xD;
          -  Persons who have used a medication (including over-the-counter drugs, topical agents,&#xD;
             vitamins, and herbal medicines) within 2 weeks prior to obtainment of consent (for an&#xD;
             immunosuppressant drug, within 60 days)&#xD;
&#xD;
          -  Persons who routinely smoke an average of more than 10 cigarettes a day (to be&#xD;
             confirmed in interview at time of screening tests) or cannot follow the rules&#xD;
             regarding smoking during the clinical trial period&#xD;
&#xD;
        Part 2:&#xD;
&#xD;
          -  Patients with severe complications judged to affect the implementation and evaluation&#xD;
             of the study in the opinion of the investigator or sub-investigator. Includes but is&#xD;
             not limited to the following. Severe cardiovascular disease (e.g., class III or IV&#xD;
             according to New York Heart Association functional classification), poorly controlled&#xD;
             diabetes mellitus (HbA1c &gt; 8.5%), poorly controlled hypertension, liver disease with&#xD;
             severity of moderate or higher (e.g., class B or C according to Child-Pugh&#xD;
             classification), kidney disease, respiratory disease, gastrointestinal disease, blood&#xD;
             dyscrasia, central nervous system disease, psychiatric disease, autoimmune disease,&#xD;
             etc.&#xD;
&#xD;
          -  Patients observed to have one of the following laboratory test abnormalities in&#xD;
             screening tests&#xD;
&#xD;
               -  Neutrophil count: &lt; 1500/μL&#xD;
&#xD;
               -  Serum creatinine: &gt; 1.5 mg/dL&#xD;
&#xD;
               -  AST or ALT: &gt; 2.5-fold the upper limit of the reference range&#xD;
&#xD;
               -  Other laboratory test abnormalities that the investigator or sub-investigator&#xD;
                  thinks could affect the completion or evaluation of the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Osaka Pharmacology Clinical research Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 17, 2019</study_first_submitted>
  <study_first_submitted_qc>February 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>January 26, 2020</last_update_submitted>
  <last_update_submitted_qc>January 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

